$INCR News
Last published 2mo ago
- 2mo agoINCRInterCure Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireNEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") announced today that it received written confirmation from the
- 2mo agoINCRInterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect DamagesGlobeNewswireCompany intends to accelerate the rehabilitation of Canndoc’s flagship Nir Oz facility, supporting a return to full production and the Company’s expansion in the growing German medical cannabis market NEW YORK and
- 2mo agoINCRInterCure Ltd. Announces 1-for-5 Reverse Share SplitGlobeNewswireStrategic Action Aimed at Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Protecting Continued Listing Status NEW YORK and HERTZLIYA, ISRAEL, Aug. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (the
- 4mo agoINCRInterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge FundsGlobeNewswire●The funding includes investments commitments from key shareholders of the Company, including the Company’s CEO Alexander Rabinovich, as well as leading pharma-focused hedge funds, including Bennu Pharma Fund Ltd.,
- 4mo agoINCRInterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico AcquisitionGlobeNewswireFirst Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and
- 6mo agoINCRInterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash FlowGlobeNewswireThe Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent
- 8mo agoINCRInterCure Receives Nasdaq Notification Regarding Minimum Bid RequirementGlobeNewswireNEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced that on February 25, 2026 the Company received a written notice
- 8mo agoINCRInterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 MillionGlobeNewswireInterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of
- 8mo agoINCRInterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 MillionGlobeNewswireInterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase
- 1y agoINCRInterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical InnovationGlobeNewswireAgreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump
- 1y agoINCRInterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash FlowGlobeNewswireThe Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA
- 1y agoINCRInterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and BrandsGlobeNewswireAcquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as
- 1y agoINCRInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025PR NewswireInterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ended December 31, 2024. All...
- 1y agoINCRInterCure Names Alexander Rabinovich as Chairman Replacing Ehud BarakPR NewswireInterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. Ehud Barak will step down as...
- 1y agoINCRInterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz FacilityPR NewswireInterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), is pleased to announce that further to the Company's prior...
- 2y agoINCRInterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionGlobeNewswireRevenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from
- 2y agoINCRInterCure Announces Expansion of its Strategic partnership with Cookies to GermanyBusiness WireInterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platforms with the official cookies retail experience, enhancing branded product
- 2y agoINCRInterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis ConferenceBusiness WireInterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis
- 2y agoINCRInterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 millionBusiness WireRevenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61 million (Approximately 17% of revenues), as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results. The
- 2y agoINCRInterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 millionBusiness WireRevenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza. However, InterCure it is entitled to full compensation from the Israeli authorities for all direct
- 2y agoINCRInterCure Congratulates Germany on Cannabis Reform, Expanding its Global FootprintBusiness WireInterCure provides an update following recent Cannabis Reform in Germany Expects to launch its first products in Germany in the coming months The Company continues to closely watch developments surrounding
- 2y agoINCRInterCure Provides an Update Regarding Nir Oz FacilityGlobeNewswireNEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel
- 2y agoINCRInterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy ChainGlobeNewswireNEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel
- 3y agoINCRInterCure Wins Cannolam Arbitration ProceedingGlobeNewswireNEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel
- 3y agoINCRInterCure Provides an Update Regarding the Security Situation in IsraelGlobeNewswireNEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel
- 3y agoINCRInterCure Announces Record Revenues First Half of 2023 with over 14% growth YOYGlobeNewswireAchieved record revenues of NIS 209 million ($75 million)1 for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149 million) Adjusted EBITDA2 of NIS 30
- 3y agoINCRInterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASEGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), announced today that its
- 3y agoINCRInterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed MergerGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), reports today that, further
- 3y agoINCRInterCure to Participate in the Cowen 3rd Annual European Cannabis ConferenceGlobeNewswireNEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander Rabinovitch, CEO of
- 3y agoINCRInterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYGlobeNewswireAchieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45 million cash and Net
- 3y agoINCRInterCure to Be Featured with Mike Tyson in an Exclusive Interview on Fox BusinessGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: INCR) (TSX:INCR) (TASE: INCR) ("InterCure'' or the "Company"), the largest and fastest growing medical cannabis
- 3y agoINCRInterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its SubsidiaryGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical
- 3y agoINCRInterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU CountriesGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, April 20, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading cannabis
- 3y agoINCRInterCure Ltd. (INCR) Q4 2022 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoINCRInterCure Reschedules 2022 Full Year Results Conference CallGlobeNewswireNEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has
- 3y agoINCRInterCure Announces Record Fourth Quarter and Fiscal Year End 2022 ResultsGlobeNewswireRecord fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong
- 3y agoINCRInterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed MergerGlobeNewswireNEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") the biggest and most profitable cannabis
- 3y agoINCRInterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)GlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that, further to
- 3y agoINCRInterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"GlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the largest and fastest
- 3y agoINCRInterCure to Participate in Cowen 5th Annual Cannabis ConferenceGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, Dec. 08, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that Alexander
- 3y agoINCRUpdate regarding Better TransactionGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, Nov. 23, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is hereby providing an
- 3y agoINCROGIOrganigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both CompaniesGlobeNewswireTORONTO and HERZILA, Israel, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), ( "Organigram"), a leading Canadian licensed producer of cannabis, and Canndoc Ltd. ("Canndoc"), a
- 3y agoINCROGITSX:INCRTSX:INCR.U+1Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both CompaniesBusiness WireOrganigram to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple years Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), ( "Organigram") a leading Canadian
- 3y agoINCRInterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growthGlobeNewswireEleventh consecutive quarter of sequential profitable revenue growth Annualized revenue run rate of $155 million Adjusted EBITDA1 run rate of $36 million Achieved Run Rate Net Profit of 12$ million
- 4y agoINCRInterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoYGlobeNewswireEstimated revenue reaches CAD$39 million1 (a record of over NIS 100 million): Eleventh consecutive quarter of profitable growth with revenue growth expected to continue in Q4 2022 NEW YORK and TORONTO and HERZLIYA,
- 4y agoINCRIntercure Ltd. Announces Voting Results from its Annual and Special Meeting of ShareholdersGlobeNewswireHERZLIYA, Israel, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Intercure Ltd. (the "Company") announces today the results of the Annual and Special General Meeting of shareholders of the Company, held on Thursday, September 15, 2022, in Bnei Brak, Israel (the "M
- 4y agoINCRInterCure Reports Record Breaking Second Quarter Financial ResultsGlobeNewswireRecord revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million i
- 4y agoINCRInterCure to Release its Q2 2022 Results and Hold a Conference CallGlobeNewswireNEW YORK and TORONTO and HERZLIYA, Israel, Aug. 11, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") today announced that it plans to release financial results for the second quar
- 4y agoINCRInterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ GrowthGlobeNewswireEstimated revenue reaches CAD$36 million 1(a record NIS 95 million) Anticipates continued increases in EBITDA Revenue growth expected to continue in Q3 and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, July 21, 2
- 4y agoCLVRCLVRWINCRClever Leaves Announces First Export to Israeli Partner InterCureGlobeNewswireBOCA RATON, Fla., July 18, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ:CLVR, CLVRW))) ("Clever Leaves" or the "Company"), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the